Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.

Journal of medicinal chemistry - 9 Nov 2017

Kaitsiotou Helena, Keul Marina, Hardick Julia, Mühlenberg Thomas, Ketzer Julia, Ehrt Christiane, Krüll Jasmin, Medda Federico, Koch Oliver, Giordanetto Fabrizio, Bauer Sebastian, Rauh Daniel

Abstract excerpt

In modern cancer therapy, the use of small organic molecules against receptor tyrosine kinases (RTKs) has been shown to be a valuable strategy. The association of cancer cells with dysregulated signaling pathways linked to RTKs represents a key element in targeted cancer therapies. The tyrosine kinase mast/stem cell growth factor receptor KIT is an example of a clinically relevant RTK. KIT is targeted for cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to Gastrointestinal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Receptor Protein-Tyrosine Kinases

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 28991465
DOI: 10.1021/acs.jmedchem.7b00841

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitors to Overcome Secondary Mutations in the Stem Cell Factor Receptor KIT.PMID 28991465Read ↗

The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.Semantic proximity Read ↗

A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitorsSemantic proximity Read ↗

Small Molecule c-KIT Inhibitors for the Treatment of Gastrointestinal Stromal Tumors: A Review on Synthesis, Design Strategies, and Structure-Activity Relationship (SAR).Semantic proximity Read ↗

C-KIT signaling in cancer treatment.Semantic proximity Read ↗

Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.Semantic proximity Read ↗

Targeting c-Kit mutations: basic science to novel therapies.Semantic proximity Read ↗

Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.Semantic proximity Read ↗

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.Semantic proximity Read ↗

Identification of M4205─A Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.Semantic proximity Read ↗

Therapeutic targeting of c-KIT in cancer.Semantic proximity Read ↗

KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.